The Key to Developing Good Manufacturing Practice (GMP) Biomaterials for Cell and Gene Therapy Development
October 3, 2022A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the […]
Overcoming the Global Biomaterial Supply Chain Challenge for the Development of CAR-T Therapies
September 21, 2022By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is […]
Dual Mobilization Enhances CD34+ Yield Across All Donor Types
August 1, 2022Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the […]
The Therapeutic Potential of HSC-based Gene Therapies
July 25, 2022Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by […]
A Decade of Innovation: CAR-T Successes and Latest Developments
July 6, 2022After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy space, continuing to forge new ground to treat previously […]
Why You Should Start Clinical Grade Cell Supply Discussions Early in Cell and Gene Therapy Development
May 24, 2022Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo […]
What You Need to Know About Regenerative Medicine in 2022: Industry and Tech Trends
April 20, 2022Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger […]
A Donor-Centric Approach to Cell and Gene Therapy
February 3, 2022In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While […]
AllCells Announces First to Market Launch of In Stock GMP Cryopreserved Leukopaks
January 28, 2022Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP Cryopreserved Leukopaks significantly decrease lead time AllCells, the industry leader in […]
FAQ Series: The Science Behind Cryopreservation
January 11, 2022Primary cells, such as those isolated from the bone marrow or peripheral blood, are important for a wide scope of research and clinical applications – from studying molecular mechanisms driving disease progression, to […]
